U.S., Sept. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07161193) titled 'Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases' on Aug. 19.
Brief Summary: The goal of this study is to evaluate the safety and efficacy of CD19 CAR T cells in the treatment of Refractory Autoimmune Diseases
Study Start Date: Sept. 30
Study Type: INTERVENTIONAL
Condition:
Autoimmune Diseases
Intervention:
BIOLOGICAL: CD19 CAR-T cells
Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with CD19 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Hebei Senlang Biotechnology Inc., ...